Drug Trial Radar · NCT06717880
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Jul 28, 2023
Primary completion
Jul 31, 2025
Study completion Jul 31, 2026
Sponsor
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer
Conditions
- Advanced Malignancies
Interventions
IBI363 combined with BevacizumabDrug
IBI363 will be administrated on Day 1 of every 2 weeks or every 3 weeks, intravenous injection. Bevacizumab, intravenous injection.
IBI363 + FuruitinibDrug
IBI363 Q2W or Q3W IV,Furuitinib po
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE)Time frame: Through out the study (up to 2 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College, Huazhong University Hospital
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.